Sexual & Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY USA.
Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Sex Med. 2022 Mar;19(3):471-478. doi: 10.1016/j.jsxm.2022.01.003. Epub 2022 Feb 5.
Prostate-specific antigen (PSA) secretion is a testosterone (T) dependent process. Published data suggest that a low T level is an independent predictor of higher-grade prostate cancer (PC).
To evaluate the relationship between T and PSA in patients with PC.
All men diagnosed with PC with a recorded pre-treatment total T level measurement were included in this analysis. We analyzed demographic, clinical, and pathological data. Patients were stratified according to pretreatment PSA levels: <2 ng/mL, 2-4 ng/mL, >4 ng/mL. Low T was defined as total T < 10.4 nmol/L (300 ng/dL), very low T < 6.9 nmol/L (200 ng/dL).
T levels by PSA groups according to the PC pathology.
In this retrospective study, mean patient age was 61 years among 646 men. The distribution by PSA group was: 8% (<2), 17% (2-4), and 76% (>4). The mean T level across the entire cohort was 13 nmol/L (374 ng/dL). Overall, 30% had a T level < 10.4 nmol/L (300 ng/dL). The mean total T level by PSA group was: <2 ng/mL, 7 nmol/L (206 ng/dL); 2-4 ng/mL, 13 nmol/L (362 ng/dL); >4 ng/mL, 14 nmol/L (393 ng/dL), P < .001. PSA <4 ng/mL was a significant predictor of low T in men with PC GS ≥8. PSA <2 ng/mL was a significant predictor of very low T independent of the PC pathology.
These findings suggest that clinicians should consider measuring T levels when a patient diagnosed with PC GS ≥8 and PSA level <4 ng/mL, and for each patient with PSA level <2 ng/mL independent of the PC pathology.
STRENGTHS & LIMITATIONS: Our study has several strengths including (i) inclusion of a large population of men, (ii) use of a database which is audited and reviewed for accuracy annually, and (iii) use of an accurate T assay (LCMS). Nonetheless, there are limitations: (i) the subjects of the study are from a single institution, and (ii) we did not measure free T levels.
In men with PC with GS ≥8, PSA level <4 ng/mL predicts low T. PSA <2 ng/mL predicts very low T independent of the PC pathology. Flores JM, Bernie HL, Miranda E, et al. The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer. J Sex Med 2022;19:471-478.
前列腺特异性抗原(PSA)的分泌是一个依赖于睾酮(T)的过程。已发表的数据表明,低 T 水平是高级别前列腺癌(PC)的独立预测因素。
评估 T 与 PC 患者 PSA 之间的关系。
本分析纳入了所有经诊断患有 PC 且记录有治疗前总 T 水平测量值的患者。我们分析了人口统计学、临床和病理数据。根据治疗前 PSA 水平将患者分层:<2ng/mL、2-4ng/mL、>4ng/mL。低 T 定义为总 T<10.4nmol/L(300ng/dL),极低 T<6.9nmol/L(200ng/dL)。
根据 PC 病理,按 PSA 分组的 T 水平。
在这项回顾性研究中,646 名男性的平均患者年龄为 61 岁。按 PSA 分组的分布为:8%(<2)、17%(2-4)和 76%(>4)。整个队列的平均 T 水平为 13nmol/L(374ng/dL)。总体而言,30%的患者 T 水平<10.4nmol/L(300ng/dL)。按 PSA 分组的平均总 T 水平为:<2ng/mL,7nmol/L(206ng/dL);2-4ng/mL,13nmol/L(362ng/dL);>4ng/mL,14nmol/L(393ng/dL),P<0.001。PSA<4ng/mL 是 PC GS≥8 男性中低 T 的显著预测因子。PSA<2ng/mL 是 PC 病理之外极低 T 的独立预测因子。
这些发现表明,当诊断为 PC GS≥8 和 PSA 水平<4ng/mL 的患者时,临床医生应考虑测量 T 水平,对于每个 PSA 水平<2ng/mL 的患者,无论 PC 病理如何,都应考虑测量 T 水平。
我们的研究有几个优势,包括(i)纳入了大量男性人群,(ii)使用了经过审核和每年审核以确保准确性的数据库,以及(iii)使用了准确的 T 检测(LCMS)。然而,也存在一些局限性:(i)研究对象来自单一机构,(ii)我们没有测量游离 T 水平。
在 GS≥8 的 PC 男性中,PSA 水平<4ng/mL 预测低 T。PSA<2ng/mL 预测 PC 病理之外的极低 T。